JAGSNPHARMNSEJagsonpal Pharmaceuticals Limited· PharmaceuticalsMediumNegative
Announced Mon, 18 May · 17:58 IST

Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding Resignation of Resignation of an Independent Director. as Non- Executive Independent Director of the company w.e.f. May 18, 2026.

Director Flagged GovernanceManagement Changes View source PDF

JAGSNPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.1%1-day move
₹198.94
prior close
₹201.07
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.2-0.5-1.5-1.3+0.1+6.6+5.1+3.9+4.1+3.5+3.0+7.1+12.1
Up moveDown movePending
AI summary

Mrs. Pallavi Dinodia Gupta has tendered her resignation as Independent Director of Jagsonpal Pharmaceuticals Limited with effect from May 18, 2026. The resignation is effective immediately. Gupta cited increasing professional commitments, personal engagements, and the need to balance existing responsibilities and health considerations as reasons for stepping down. As a result, she will cease to be a member of the Audit Committee, Corporate Social Responsibility Committee, and chairperson of the Stakeholders Relationship Committee. She has confirmed there are no material reasons for her resignation beyond those stated. Gupta holds independent directorships in three other listed companies: IndiaMART InterMESH Limited, Voith Paper Fabrics India Limited, and Lumax Industries Limited.

Likely market impact

The departure of an Independent Director and committee chair removes board independence and could raise governance concerns for investors, particularly affecting audit and stakeholder oversight structures.